Two prescriptions sit in the same drawer more often than any other pair this site covers: a weekly injection for weight, and a daily pill for birth control. Whether the first disturbs the second has a precise answer, and the answer depends entirely on which injection it is. One molecule’s label tells a reader to add a second method of contraception. The other molecule’s label does not use the word. That gap is not an oversight, and it is not a difference in how carefully the two companies wrote — it follows from what each company measured.
The instruction, quoted
The tirzepatide labels carry a section headed Contraception, and its first sentence states the reason: “Use of ZEPBOUND may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying. This delay is largest after the first dose and diminishes over time.” The instruction that follows is to “switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation.”[1] The diabetes-branded product carries the same paragraph with its own name substituted.[2] Both add that hormonal contraceptives not administered orally should not be affected. Why the window reopens at every dose step, rather than closing after the first month, is worked through in the contraception and pregnancy article.
Now the semaglutide side. Searched as a document, the weight-management label does not contain the string “contracept” anywhere. What it contains instead is this, inside its clinical pharmacology section: “No clinically significant differences in the pharmacokinetics of the following drugs were observed when used concomitantly with semaglutide: lisinopril, S-warfarin, R-warfarin, metformin, digoxin, ethinyl estradiol, levonorgestrel, furosemide or rosuvastatin.”[3] The two hormones in a combined pill are named — in a list of drugs that nothing happened to. The general caution in the same label is the one that covers every swallowed drug in the class, and it asks for extra monitoring where the therapeutic index is narrow. A contraceptive is not in that category, so no instruction attaches.
Four molecules were tested and nothing happened
The asymmetry is easier to trust once the other studies are laid out, because there are more of them than most summaries admit. Forty-three postmenopausal women with type 2 diabetes took ethinyl estradiol 0.03 mg with levonorgestrel 0.15 mg for eight days without semaglutide and eight days with it at a steady-state 1.0 mg weekly. Exposure to the estrogen met the bioequivalence criterion at a ratio of 1.11 (1.06 to 1.15); the progestin came in 20% higher, at 1.20 (1.15 to 1.26). Peak concentration stayed inside the criterion for both.[4] Note the direction. The one component that moved moved upward.
The swallowed form of semaglutide was tested the same way, and it is the harder test, because a tablet carrying an absorption enhancer has two ways to interfere rather than one. Twenty-five healthy postmenopausal women received the same combined pill alone, with the enhancer alone, and with oral semaglutide. Exposure ratios came back at 1.06 for the estrogen (1.01 to 1.10) and 1.06 for the progestin (0.97 to 1.17), with peak concentration unaffected and the enhancer alone doing nothing.[5] The route distinction that makes that a separate question is set out in the comparison of the two delivery routes.
Dulaglutide was given alongside a norgestimate pill in a study whose conclusion is embedded in its title: no dose adjustment is recommended. Peak concentrations were generally lower and time to peak generally later, while total exposure was similar.[6] And liraglutide, with the pill taken seven hours after the injection, lowered peak concentrations of the estrogen and the progestin by 12% and 13%, left estrogen exposure untouched, raised progestin exposure 18%, and pushed both peaks back an hour and a half.[7] Liraglutide is the instructive control here: a real, measured, published effect on a contraceptive, attached to no instruction at all, because the size of it did not warrant one.
Exenatide shows that the clock matters more than the drug
The oldest study in this set is also the one that best explains the mechanism, because it varied the timing on purpose. Thirty-two healthy women took a combined pill in three arrangements: alone, one hour before an exenatide injection, and thirty minutes after one.
Taken an hour before the injection, nothing substantive changed. Taken thirty minutes after, single-dose peak concentrations fell 46% (90% CI, 42 to 51) for the estrogen and 41% (35 to 47) for the progestin, with peaks arriving three to four hours late. Across repeated daily dosing the estrogen peak was still 45% lower. Bioavailability was not altered, and daily trough concentrations did not fall.[8] The authors’ own conclusion is a scheduling note rather than an alarm: the reduction is of limited importance given unchanged bioavailability, but for drugs that depend on a threshold concentration, take them at least an hour before the injection.
That is the whole mechanism in one experiment. A slowed stomach moves when a pill arrives, not how much of it arrives. The same pill, the same drug, the same person — a ninety-minute difference in timing turns a 46% effect into none.
So why does tirzepatide get a rule?
Because its numbers are larger, and because the falls in peak concentration are accompanied by falls in total exposure rather than rises. In the single published study, a 5 mg dose given with a combined pill cut peak concentrations of the estrogen and both progestin components by more than half, cut total exposure by about a fifth for each, and delayed the peak by up to four and a half hours.[9] A 2024 review that compared all six available trials side by side reached the obvious conclusion: one agent showed a statistically significant reduction, the other five did not, and the difference tracks the steeper delay in gastric emptying after a first or an increased dose.[10]
That review also names the real driver, which is the dosing calendar rather than the molecule. Tirzepatide’s effect on emptying is largest at a dose the body has not met before and fades as the dose repeats, which is why the labeled precaution is four weeks long and attached to each step of the escalation schedule rather than to the whole course. A reader who has been at the same dose for six months is not in the same situation as one who stepped up last Tuesday, even though they are taking the same two medicines.
A lower peak is not a failed pill, and nobody has counted one
The number most often quoted from the tirzepatide study is the largest one, and it is the least informative. A 2026 review makes the point carefully: exposure to the active progestin metabolite fell far less than its peak did, which demonstrates that a fall in peak concentration cannot be equated with reduced effectiveness.[11] Combined pills work by maintaining a concentration across the day, not by hitting a spike each morning, and trough concentrations are the quantity that speaks to that. Exenatide’s troughs did not fall.[8]
Here is the sentence that belongs at the end of every article on this subject and appears in almost none of them. No study of any drug in this class has measured a contraceptive outcome. Not a pregnancy rate, not an ovulation rate, not breakthrough bleeding. Every figure above is a plasma concentration in a small group of volunteers, several of them postmenopausal and therefore incapable of demonstrating the endpoint that matters. The tirzepatide instruction is a precaution derived from a pharmacokinetic result, which is a defensible thing for a regulator to require and a different thing from evidence that pills have failed.
Two further gaps deserve naming. Progestogen-only pills, which a great many people take, have never been studied with any of these drugs, and the 2026 review states in terms that findings from one contraceptive formulation cannot be carried over to a structurally different one.[11] And the labeled reassurance about non-oral methods rests on mechanism rather than measurement: an implant or an intrauterine device never passes through a stomach, so there is nothing for a slowed stomach to do, but no trial confirmed it.
What this changes for someone buying online
The practical difference between the two molecules is real and it is narrow. Someone on compounded or branded tirzepatide who also takes a daily pill has a labeled precaution that reopens at each dose increase. Someone on semaglutide has a label that lists their contraceptive among the drugs nothing happened to. Choosing between the molecules on any other basis is covered in the molecule comparison, and this is one more line in that ledger rather than a reason to reconsider either.
One caution specific to this market. Compounded semaglutide and compounded tirzepatide are not approved by the FDA and are not reviewed by the agency for safety, effectiveness or quality before a pharmacy ships them, which means the labeled contraception text above travels with the branded product and not with a compounded vial. The pharmacology is the same molecule; the document that would have told a buyer about it is not in the box. Nothing here is a reason to start, stop or change any medication on your own, and how claims on this site are established is set out in the methodology.